The Company expects that cash, cash equivalents, and short-term investments as of June 30, 2025, will enable the Company to fund its operating expenses and capital expenditure requirements through the end of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Buy Rating for Rapport Therapeutics, Inc. Driven by Promising Phase IIa Trial and RAP Technology Potential
- Buy Rating for Rapport Therapeutics: RAP-219’s Promising Potential in Epilepsy Treatment
- Rapport Therapeutics initiated with a Buy at H.C. Wainwright
- Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
- Rapport Therapeutics files to sell 470,589 shares of common stock for holders